Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTONASDAQ:CURNASDAQ:FRTXNASDAQ:ONVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsCURNeuralstem$0.73-1.9%$1.06$1.10▼$13.78$1.52M1.81236,278 shs145,298 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%-53.78%-92.30%CURNeuralstem+5.42%+14.81%-8.38%+6.39%-84.00%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+3.89%ONVOOrganovo0.00%0.00%0.00%-13.92%-77.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.9167 of 5 stars3.80.00.00.03.20.00.0CURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideCURNeuralstem 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AONVOOrganovo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CUR, FRTX, APTO, and ONVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $6.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/ACURNeuralstem$260K5.86N/AN/A$6.64 per share0.11FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/ACURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05CURNeuralstemN/A2.532.53FRTXFresh Tracks TherapeuticsN/AN/AN/AONVOOrganovoN/A0.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%CURNeuralstem38.30%FRTXFresh Tracks Therapeutics25.04%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%CURNeuralstem5.38%FRTXFresh Tracks Therapeutics0.23%ONVOOrganovo3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataCURNeuralstem62.10 millionN/ANot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableONVOOrganovo201.70 million14.79 millionOptionableCUR, FRTX, APTO, and ONVO HeadlinesRecent News About These CompaniesDriven! The Onvo L60 Is China’s Best Tesla Model Y Killer to DateMay 18, 2025 | msn.comTwo new option listings and one option delisting on April 24thApril 25, 2025 | markets.businessinsider.comVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketApril 24, 2025 | globenewswire.comOrganovo announces VivoSim to carry forward 3D bioprinting, legacy techApril 23, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS"April 23, 2025 | quiverquant.comQVivoSim to Carry Forward Organovo 3D BioprintingApril 23, 2025 | globenewswire.comOrganovo expects to meet requirements for continued listing on NasdaqApril 2, 2025 | markets.businessinsider.comOrganovo Holdings Expects to Meet Nasdaq Listing RequirementsApril 2, 2025 | tipranks.comOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | financialpost.comFOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | globenewswire.comOrganovo sees cash runway through the end of FY26March 28, 2025 | markets.businessinsider.comOrganovo, Inc.: Organovo Provides Business UpdateMarch 27, 2025 | finanznachrichten.deOrganovo Provides Business UpdateMarch 27, 2025 | financialpost.comFOrganovo Provides Business UpdateMarch 27, 2025 | globenewswire.comOrganovo, Inc.: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 26, 2025 | finanznachrichten.deOrganovo closes sale of FXR program to Eli LillyMarch 25, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Completes Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | quiverquant.comQOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | globenewswire.comOrganovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq ComplianceMarch 21, 2025 | nasdaq.comOrganovo trading halted, news pendingMarch 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBuy The Dip in Okta, There’s Nothing Wrong With the OutlookBy Thomas Hughes | June 2, 2025View Buy The Dip in Okta, There’s Nothing Wrong With the OutlookCUR, FRTX, APTO, and ONVO Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
